Clinical Research

Thumbnail

New research suggests immunotherapy for AFib could be on the horizon

Targeting immune cells that play a key role in the development of atrial fibrillation could give cardiologists a new way to treat the disease.

Thumbnail

PROMISE trial results reinforce confidence in new MRI contrast agent

The randomized, double-blinded phase 3 study revealed gadopiclenol to be noninferior to gadobutrol for all qualitative visualization parameters as rated by all blinded readers involved in the trial.

NIST researchers improve portable MRI

Improving low-field MRI scanners with quantitative data

Researchers at the National Institute of Standards and Technology (NIST) are working on developing measurements that will provide better insight into soft tissue properties visualized on portable MRI images. 

radiology reporting EHR health record CDS AUC

ImpressionGPT, a ChatGPT-based framework, can accurately summarize radiology reports

The program leverages the in-context learning abilities of large language models to generate report summaries using domain-specific, individualized data relative to radiology.

Thumbnail

New discovery paves the way for copper's entrance into MRI contrast agents

The new discovery contradicts the notion that copper is not suitable for use in contrast media.

The ReCor (left) and Medtronic Symplicity Spyral renal denervation systems.

FDA panel to review renal denervation system PMA submissions

The FDA Circulatory System Devices Panel is set to review the PMA submissions for the ReCor and Medtronic renal denervation systems to treat patients with uncontrolled hypertension.

The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment.

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

A figure from the study shows a chest radiograph with an area of consolidation involving right lower lung consistent with pneumonia, as well as right pleural effusion. The deep-learning model predicted risk of 30-day mortality of 9%. Right: Gradient- weighted class activation map shows that model prediction was influenced by separate area of image corresponding with heart and liver (yellow and light blue colors). Patient’s CURB-65 score was 4. Patient recovered from pneumonia and remained alive. AJR Image

Deep learning predicts pneumonia mortality on chest X-rays

AI was able to predict 30-day mortality risk predictions more accurately that the current risk assessment.